CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of CPI-613 when given together with
combination chemotherapy in treating patients with metastatic pancreatic cancer. Drugs used
in chemotherapy, CPI-613, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and
oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing.